These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 21670542)

  • 1. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study-.
    Ogawa S; Shinohara Y; Kanmuri K
    Circ J; 2011; 75(8):1852-9. PubMed ID: 21670542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.
    Halvorsen S; Atar D; Yang H; De Caterina R; Erol C; Garcia D; Granger CB; Hanna M; Held C; Husted S; Hylek EM; Jansky P; Lopes RD; Ruzyllo W; Thomas L; Wallentin L
    Eur Heart J; 2014 Jul; 35(28):1864-72. PubMed ID: 24561548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.
    Easton JD; Lopes RD; Bahit MC; Wojdyla DM; Granger CB; Wallentin L; Alings M; Goto S; Lewis BS; Rosenqvist M; Hanna M; Mohan P; Alexander JH; Diener HC;
    Lancet Neurol; 2012 Jun; 11(6):503-11. PubMed ID: 22572202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Alexander JH; Lopes RD; Thomas L; Alings M; Atar D; Aylward P; Goto S; Hanna M; Huber K; Husted S; Lewis BS; McMurray JJ; Pais P; Pouleur H; Steg PG; Verheugt FW; Wojdyla DM; Granger CB; Wallentin L
    Eur Heart J; 2014 Jan; 35(4):224-32. PubMed ID: 24144788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial.
    Jaspers Focks J; Brouwer MA; Wojdyla DM; Thomas L; Lopes RD; Washam JB; Lanas F; Xavier D; Husted S; Wallentin L; Alexander JH; Granger CB; Verheugt FW
    BMJ; 2016 Jun; 353():i2868. PubMed ID: 27306620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.
    Guimarães PO; Pokorney SD; Lopes RD; Wojdyla DM; Gersh BJ; Giczewska A; Carnicelli A; Lewis BS; Hanna M; Wallentin L; Vinereanu D; Alexander JH; Granger CB
    Clin Cardiol; 2019 May; 42(5):568-571. PubMed ID: 30907005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban versus warfarin in patients with atrial fibrillation.
    Granger CB; Alexander JH; McMurray JJ; Lopes RD; Hylek EM; Hanna M; Al-Khalidi HR; Ansell J; Atar D; Avezum A; Bahit MC; Diaz R; Easton JD; Ezekowitz JA; Flaker G; Garcia D; Geraldes M; Gersh BJ; Golitsyn S; Goto S; Hermosillo AG; Hohnloser SH; Horowitz J; Mohan P; Jansky P; Lewis BS; Lopez-Sendon JL; Pais P; Parkhomenko A; Verheugt FW; Zhu J; Wallentin L;
    N Engl J Med; 2011 Sep; 365(11):981-92. PubMed ID: 21870978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
    Held C; Hylek EM; Alexander JH; Hanna M; Lopes RD; Wojdyla DM; Thomas L; Al-Khalidi H; Alings M; Xavier D; Ansell J; Goto S; Ruzyllo W; Rosenqvist M; Verheugt FW; Zhu J; Granger CB; Wallentin L
    Eur Heart J; 2015 May; 36(20):1264-72. PubMed ID: 25499871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
    Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
    Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial.
    Dalgaard F; Mulder H; Wojdyla DM; Lopes RD; Held C; Alexander JH; De Caterina R; Washam JB; Hylek EM; Garcia DA; Gersh BJ; Wallentin L; Granger CB; Al-Khatib SM
    Circulation; 2020 Jan; 141(1):10-20. PubMed ID: 31747786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-Related Differences in the Clinical Characteristics and Treatment of Elderly Patients With Atrial Fibrillation in Japan　- Insight From the ANAFIE (All Nippon AF In Elderly) Registry.
    Hiasa KI; Kaku H; Inoue H; Yamashita T; Akao M; Atarashi H; Koretsune Y; Okumura K; Shimizu W; Ikeda T; Toyoda K; Hirayama A; Yasaka M; Yamaguchi T; Teramukai S; Kimura T; Kaburagi J; Takita A; Tsutsui H
    Circ J; 2020 Feb; 84(3):388-396. PubMed ID: 31969518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial.
    Bahit MC; Lopes RD; Wojdyla DM; Hohnloser SH; Alexander JH; Lewis BS; Aylward PE; Verheugt FW; Keltai M; Diaz R; Hanna M; Granger CB; Wallentin L
    Int J Cardiol; 2013 Dec; 170(2):215-20. PubMed ID: 24192334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study.
    Himmler S; Müller M; Ostwald D; Seddik A; Basic E; Hradetzky E
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):223-230. PubMed ID: 30295561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial.
    Washam JB; Hohnloser SH; Lopes RD; Wojdyla DM; Vinereanu D; Alexander JH; Gersh BJ; Hanna M; Horowitz J; Hylek EM; Xavier D; Verheugt FWA; Wallentin L; Granger CB;
    J Thromb Thrombolysis; 2019 Apr; 47(3):345-352. PubMed ID: 30790160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
    Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L;
    Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.
    Stanifer JW; Pokorney SD; Chertow GM; Hohnloser SH; Wojdyla DM; Garonzik S; Byon W; Hijazi Z; Lopes RD; Alexander JH; Wallentin L; Granger CB
    Circulation; 2020 Apr; 141(17):1384-1392. PubMed ID: 32160801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
    Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U
    J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.